Who is sponsoring NCT05551624?

NCT05551624 is sponsored by Hospital Civil de Guadalajara.

What drugs are being tested in NCT05551624?

Interventions in NCT05551624: Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet.

What condition does NCT05551624 study?

NCT05551624 studies Primary Immune Thrombocytopenia.

Is NCT05551624 still recruiting?

NCT05551624 is currently completed. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT05551624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

Completed EARLY_PHASE1 Last updated 22 September 2022

What this trial tests

EARLY_PHASE1 trial testing Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet in Primary Immune Thrombocytopenia in 15 participants. Completed in 23 January 2020.

Timeline

4 July 2018

Primary endpoint
11 December 2019

23 January 2020

Quick facts

Lead sponsor	Hospital Civil de Guadalajara
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	4 July 2018
Primary completion	11 December 2019
Estimated completion	23 January 2020
Sites	1 location across Mexico

Drugs / interventions tested

Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet — full drug profile →

Conditions studied

Primary Immune Thrombocytopenia — all drugs for Primary Immune Thrombocytopenia →

Sponsor

Hospital Civil de Guadalajara

Who can join

15 and older, any sex, with Primary Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia.
Allegra A, Cicero N, Mirabile G, Giorgianni CM, et al · · 2023 · cited 17× · PMID 36901864 · DOI 10.3390/ijms24054438
Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial.
Cervantes-Pérez LA, Cervantes-Guevara G, Cervantes-Pérez E, Cervantes-Cardona GA, et al · · 2023 · PMID 37374326 · DOI 10.3390/medicina59061122

Verify or expand the search:

Other recruiting trials for Primary Immune Thrombocytopenia

Currently open trials in the same condition.

NCT07039422 — Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (w · Phase 2 · recruiting
NCT06531018 — Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. · Phase 1, PHASE2 · recruiting
NCT06686927 — Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP · Phase 2 · recruiting
NCT06594146 — Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) · Phase 2 · active not recruiting
NCT06658834 — A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP · Phase 2 · recruiting

Other Hospital Civil de Guadalajara trials

Trials by the same sponsor.

NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting
NCT07436130 — Curcumin in Critically Ill Patients With Sepsis · NA · not yet recruiting
NCT07224997 — Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections · Phase 2 · not yet recruiting
NCT07205627 — Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial · NA · not yet recruiting
NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05551624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Civil de Guadalajara
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing